Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is approaching an unusually consequential regulatory test in schizophrenia with a medicine whose active ingredient has been used for decades. At Psych Congress 2026, the company reported that 56% of 411 participants receiving investigational once-monthly olanzapine extended-release injection TEV-’749 achieved predefined stabilization during the long-term phase of the Phase 3 SOLARIS programme. Among the 231 participants who reached stabilization, just 10, or about 4%, subsequently relapsed, while 39 of 183 participants treated for at least six months met the study’s criteria for remission.
Those numbers are encouraging, but they are not the main reason TEV-’749 could matter commercially. Teva is attempting to solve a logistical problem that has restricted long-acting olanzapine in the United States for years. The currently available depot formulation carries an FDA-required risk-management programme because of post-injection delirium/sedation syndrome, requiring administration at a certified facility followed by at least three hours of observation. Teva’s subcutaneous formulation has so far produced no suspected or confirmed PDSS events across 3,470 injections in the completed SOLARIS programme, creating the possibility that physicians could eventually use long-acting olanzapine without imposing that same monitoring burden. Whether FDA reviewers agree that the evidence supports a materially simpler post-injection workflow remains one of the most commercially important questions ahead of the expected fourth-quarter 2026 decision.
Why has olanzapine been difficult to turn into a practical long-acting treatment?
Olanzapine is not an experimental antipsychotic trying to prove that its mechanism works. It is an established second-generation antipsychotic widely used in schizophrenia, with extensive clinical experience supporting its ability to control psychotic symptoms. Teva describes it as one of the most commonly prescribed atypical antipsychotics, while the clinical challenge has increasingly centred on how to maintain treatment reliably rather than whether olanzapine itself can reduce symptoms.
Long-acting injectable antipsychotics attempt to reduce one of schizophrenia treatment’s persistent vulnerabilities: a daily tablet can only work consistently when it is taken consistently. Treatment interruptions can occur for many reasons, including adverse effects, limited insight into illness, unstable living circumstances and the practical difficulty of maintaining daily therapy over years. Relapse can lead to emergency care, hospitalization and further functional disruption, giving clinicians a reason to consider long-acting treatment even when the active drug is already available orally.
Olanzapine’s existing long-acting formulation introduced an unusual obstacle. Post-injection delirium/sedation syndrome resembles acute olanzapine overdose and can produce sedation, confusion, slurred speech, disorientation, dizziness and altered gait. An analysis of roughly 45,000 injections administered during clinical development estimated PDSS in approximately 0.07% of injections and 1.4% of exposed patients, with onset ranging from immediately after administration to several hours later.
Because the event is uncommon but potentially serious and unpredictable, the U.S. risk-management programme requires patients receiving the existing depot to remain under observation after every injection. A medicine intended partly to simplify adherence consequently creates a recurring three-hour healthcare encounter. That trade-off has made olanzapine fundamentally different from several other long-acting antipsychotics whose administration does not require the same extended observation period.
What is different about TEV-’749 if the active drug is still olanzapine?
TEV-’749 changes the delivery system rather than the pharmacological target. The investigational medicine uses Medincell’s polymer technology, licensed by Teva under the SteadyTeq name, to create a controlled subcutaneous depot that releases olanzapine over approximately one month. The three studied doses, 318 mg, 425 mg and 531 mg, were designed to correspond broadly with daily oral olanzapine exposures of 10 mg, 15 mg and 20 mg.
This subcutaneous approach differs from the established intramuscular olanzapine pamoate depot. PDSS with the older formulation is thought to occur when an unexpectedly large amount of olanzapine enters the bloodstream rapidly after injection, producing symptoms consistent with overdose. Teva’s formulation is designed around controlled release from a polymer depot, although the absence of PDSS observed to date should not be interpreted as proof that the event is impossible. Only the FDA can determine the final warnings, monitoring requirements and risk-management conditions if TEV-’749 is approved.
The regulatory distinction could decide much of the product’s value. A once-monthly olanzapine injection that still required patients to remain in a facility for three hours would improve dosing frequency but preserve a major operational disadvantage. A formulation that did not require such monitoring could fit far more naturally into community psychiatry, outpatient clinics and routine long-acting injectable programmes.
That is why “no PDSS observed” is more strategically important than a typical safety footnote. Teva is not merely trying to launch another depot. It is trying to make an already effective molecule operationally competitive with modern long-acting antipsychotics.
How convincing is the absence of PDSS across the SOLARIS programme?
The completed SOLARIS long-term safety analysis included 3,470 TEV-’749 injections through Week 56 without a suspected or confirmed PDSS event. The programme initially randomized 675 adults with schizophrenia across three active-dose groups and placebo during an eight-week double-blind period before continuing into a longer open-label safety phase.
That is a reassuring dataset because the historical PDSS event rate with conventional olanzapine depot was low enough that small studies could easily miss cases. Several thousand injections provide a more meaningful exposure base than a few hundred administrations.
The comparison still requires caution. The absence of observed cases does not mathematically demonstrate zero risk, and TEV-’749 is a different formulation administered through a different route. It would therefore be inappropriate to take the historical event rate from the older product, apply it directly to TEV-’749 and claim statistical proof that the new product eliminates PDSS.
The FDA will instead consider the total formulation, pharmacokinetic, clinical and safety evidence. Teva’s February NDA-acceptance announcement stated that the SOLARIS programme showed no evidence suggesting the need for post-injection monitoring, but that remains the sponsor’s interpretation until the agency completes its review and establishes the approved label.
Did TEV-’749 demonstrate enough efficacy to justify monthly treatment?
The controlled eight-week portion of SOLARIS provides the clearest evidence. All three TEV-’749 dose groups produced statistically significant improvements in Positive and Negative Syndrome Scale scores compared with placebo. The adjusted differences in change from baseline were approximately 9.7 points for the 531 mg dose, 11.25 points for the 425 mg dose and 9.69 points for the 318 mg dose, with all comparisons reaching p-values below 0.0001 in Teva’s presentation. Clinical Global Impression-Severity and Personal and Social Performance measures also favoured active treatment.
The newly presented Psych Congress results address a different question: what happens after patients continue treatment? Among 411 participants included in the current post hoc analysis, 231 achieved stabilization. Only 10 of those stabilized participants subsequently met relapse criteria, while 21% of the 183 people exposed for at least six months reached the analysis definition of remission.
Those figures should not be read as though 96% of every patient starting TEV-’749 will remain relapse-free. The 4% relapse proportion applies specifically to participants who first achieved stabilization, while the long-term period was open label and the latest analysis was post hoc rather than a prospectively powered placebo-controlled relapse comparison.
Even with those limitations, the data address an important practical issue. Long-acting therapy is valuable only if symptom control persists between injections. The combination of controlled acute efficacy and longer-term maintenance data supports Teva’s argument that monthly delivery does not appear to sacrifice olanzapine’s established therapeutic effect.
Is TEV-’749 really solving adherence if patients still need monthly injections?
Long-acting injectables do not eliminate adherence. They transform it.
With an oral antipsychotic, clinicians may have limited visibility into whether a patient has actually taken medication between appointments. With a monthly injection, treatment exposure becomes observable. A missed appointment is evident, allowing healthcare teams to intervene rather than discovering treatment discontinuation only after symptoms worsen.
One injection each month also reduces the number of medication-taking decisions from hundreds each year to roughly 12 scheduled administrations. That can be important in a disease where impaired insight may itself be part of the illness.
Yet injections introduce their own barriers. Patients must return to a healthcare setting, accept repeated injections and tolerate local reactions. Transportation, appointment availability and insurance authorization can still disrupt treatment.
The commercial value of TEV-’749 therefore depends on whether its monthly workflow is sufficiently simple. Eliminating a three-hour monitoring requirement could make the difference between an injection that merely exists and one that can be incorporated routinely into busy psychiatric practices.
Does removing PDSS leave olanzapine’s metabolic problem unchanged?
This is the principal counterweight to the excitement around the formulation. TEV-’749 may address a delivery-specific safety problem, but it does not remove olanzapine’s established metabolic effects.
Across the long-term SOLARIS analysis, increased weight was reported in 36% of participants. Among 137 people treated for at least 48 weeks, mean weight gain was 5.6 kilograms, which Teva said was comparable with weight changes observed with existing olanzapine formulations. Injection-site induration occurred in 12%, injection-site pain in 12%, erythema in 10%, pruritus in 7% and somnolence in 7%.
This creates an important distinction between formulation improvement and molecule improvement. TEV-’749 may make olanzapine easier to administer long term, but it does not turn olanzapine into a metabolically neutral antipsychotic.
Physicians considering treatment will still need to weigh efficacy against weight gain and metabolic risk. Some patients respond exceptionally well to olanzapine or have previously demonstrated good symptom control with oral treatment, making a long-acting version particularly attractive. Others may be better served by a different antipsychotic because of obesity, diabetes risk or previous metabolic intolerance.
The addressable market is therefore unlikely to be every person with schizophrenia. The most obvious population may be patients for whom olanzapine is already clinically appropriate but daily oral adherence is uncertain or inconvenient.
Could switching existing oral olanzapine patients create the fastest commercial opportunity?
Teva’s September Psych Congress presentation included analyses specifically examining how patients might transition from established oral or injectable antipsychotic regimens into TEV-’749. That work is commercially relevant because physicians often hesitate to switch stable patients when dosing conversions are unclear.
The most natural initial target is likely to be people already taking oral olanzapine successfully. In those patients, the efficacy and molecule-specific tolerability questions are partly answered by their existing treatment experience. The decision becomes whether long-acting delivery provides enough adherence or convenience advantage to justify changing formulation.
This differs from persuading physicians to move patients from another effective long-acting molecule. A stable patient receiving risperidone, paliperidone or aripiprazole may have little reason to change unless efficacy, tolerability or treatment preferences create a clear need.
TEV-’749 could therefore expand long-acting treatment partly by converting patients who currently use oral olanzapine rather than simply stealing share from other injectable brands.
Why does the programme matter so much to Teva Pharmaceutical Industries?
TEV-’749 sits directly inside Teva’s attempt to change its financial identity from a company heavily associated with generic pharmaceuticals into one deriving more growth from proprietary medicines. Second-quarter 2026 revenue was $4.14 billion, down 1% year over year in reported currency, largely because of lower generic revenue. At the same time, the company’s three highlighted innovative brands, AUSTEDO, AJOVY and UZEDY, generated more than $1 billion collectively and grew 43% in local-currency terms.
The schizophrenia franchise is already contributing to that transition. UZEDY, Teva’s long-acting risperidone product using the same underlying Medincell polymer-delivery technology, produced $77 million in second-quarter revenue, up 43% year over year in local-currency terms. Teva raised its 2026 UZEDY revenue outlook to approximately $270 million to $290 million.
TEV-’749 could allow the company to address a different treatment population using commercial infrastructure it is already building for long-acting psychiatry. Sales representatives, payer relationships, injection-site training and psychiatric-provider networks created around UZEDY can potentially support another schizophrenia product rather than being developed from scratch.
That portfolio effect makes TEV-’749 more valuable to Teva than an isolated drug launch might appear.
What does current investor sentiment suggest ahead of the FDA decision?
Teva’s New York-listed shares closed at $38.98 on September 18, down 0.54% for the session but close to the recent 52-week high of $39.70. Compared with the $30.95 closing price on January 2, the stock has gained about 26% during 2026 by simple calculation.
That performance should not be attributed specifically to TEV-’749. Investors are simultaneously pricing strong AUSTEDO and AJOVY growth, UZEDY expansion, pipeline assets, generics performance, debt and Teva’s wider effort to improve margins and reposition the company around innovative medicines.
Nevertheless, TEV-’749 fits the narrative investors increasingly appear to be evaluating: can Teva convert its established neuroscience capabilities and formulation technologies into proprietary products capable of offsetting pressure in traditional generics?
An FDA approval with a favourable monitoring profile would reinforce that strategy. Approval accompanied by onerous observation requirements would still create a commercial medicine but weaken one of the programme’s principal differentiation arguments.
What exactly should investors and psychiatrists watch in the FDA decision?
The binary question is whether TEV-’749 is approved. The more informative question is how it is approved.
The final label will establish warnings, administration requirements and whether FDA believes any specific post-injection monitoring is necessary. That language could materially influence treatment-centre economics and physician willingness to prescribe the product.
Pricing will also matter. Teva needs to position TEV-’749 against inexpensive generic oral olanzapine and several established long-acting injectable antipsychotics. The economic argument will therefore need to incorporate adherence, relapse prevention, healthcare utilization and convenience rather than drug acquisition cost alone.
Commercial uptake will then reveal whether physicians see a genuinely underserved group of olanzapine-responsive patients who want or need long-acting treatment.
TEV-’749 is unusual precisely because its scientific proposition is not especially mysterious. Olanzapine’s ability to treat schizophrenia has been understood for decades. The unresolved problem has been how to deliver that efficacy over long intervals without adding a safety-management burden large enough to undermine the convenience of the injection itself.
Across 3,470 SOLARIS injections, Teva has not observed a suspected or confirmed PDSS event. The latest long-term analysis also suggests that patients who stabilize can maintain symptom control over continued treatment. Those findings bring TEV-’749 close to answering a question schizophrenia treatment has carried for years: can olanzapine finally become a practical modern long-acting injectable?
The FDA’s fourth-quarter decision may determine whether the answer is yes, but the decisive detail could be buried deeper than the approval headline. If the eventual label allows physicians to administer once-monthly olanzapine without sending every patient into a three-hour observation period, Teva may have solved a formulation problem that has constrained one of psychiatry’s most established medicines far more than its efficacy ever did.
